Tag Archives: XALIA
September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11
The French rivaroxaban experience: what we call progress is the exchange of one nuisance for another*
Thibault Leclerq, Samuel Goussot, Karim Stamboul, Yves Cottin, Luc Lorgis
*citation from Havelock Ellis ‘Impressions and Comments’ Introduction Rivaroxaban is an oral direct factor Xa inhibitor belonging to the novel oral anticoagulants (NOACs) class. Concerning efficacy and tolerability, it has been reported to be more effective than enoxaparin in preventing venous thromboembolism in patients undergoing orthopaedic surgery,1,2 and was non-inferior to enoxaparin followed by warfarin in a study involving patients with established venous thrombosis.3 Its good bioavailability, rapid-action and a half-life of 5–13 h,4 associated with a highly reproducible anticoagulant activity and the same rate of bleeding compl
For healthcare professionals only
